Stockreport

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Editas Medicine, Inc.  (EDIT) 
Last editas medicine, inc. earnings: 2/26 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.editasmedicine.com
PDF CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported in vivo preclinical proof-o [Read more]